Endotrophin as a Marker of Complications in a Type 2 Diabetes Cohort

figure

posted on 2022-09-12, 11:50 authored by Ninna Hahn Tougaard, Alexandra Louise Møller, Pernille Falberg Rønn, Tine Willum Hansen, Federica Genovese, Morten Asser Karsdal, Daniel Guldager Kring Rasmussen, Peter Rossing

Objective
We investigated endotrophin, a profibrotic signaling molecule reflecting collagen VI formation, in serum and urine as risk marker for complications to type 2 diabetes.
Research Design and Methods
Endotrophin was measured in 774 persons with type 2 diabetes. Outcomes included a composite kidney endpoint, first major adverse cardiovascular event (MACE), mortality, progression of albuminuria, incident heart failure and sight-threatening eye disease. Adjusted cox proportional hazards models were applied.
Results

Doubling of serum endotrophin was associated with the kidney endpoint (n=49, HR:1.80 (95% CI: 1.13-2.87), first MACE (n=66, HR:1.54 (1.04-2.28)), mortality (n=156, HR:1.69 (1.31-2.19)) and incident heart failure (n=42, HR:1.63 (1.02-2.60)). A doubling of urine endotrophin was associated with progression of albuminuria (n=85, HR:1.20 (1.04-1.39)) and incident heart failure (n=40, HR:1.79 (1.09-2.95)).

Conclusions
Serum endotrophin was a risk marker for mortality, kidney and cardiovascular complications in type 2 diabetes. Urine endotrophin was a marker for albuminuria progression and heart failure.